Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02980874 · ClinicalTrials.gov registry record · Phase 3
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
A Phase 3 study, sponsored by Clearside Biomedical.
- Terminated
- Registry status
- Phase 3
- Development phase
- 460
- Enrollment target
NCT02980874 is a Phase 3 study that was terminated before completion, run by Clearside Biomedical. The registered enrollment target is 460 participants.
The verdict
NCT02980874, a Phase 3 study, was terminated before completion, sponsored by Clearside Biomedical.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 460 participants
- Enrollment target
Study Summary
This is a Phase 3, multicenter, randomized, masked, controlled, parallel group study of 12 months duration in treatment naïve subjects with RVO.
Interventions
- DRUG IVT aflibercept
- DRUG suprachoroidal CLS-TA
- DRUG suprachoroidal sham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Start Date | 2017-01-31 |
| Est. Completion | 2018-12-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02980874
The ClinicalTrials.gov registry entry for NCT02980874 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 460 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clearside Biomedical, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which IVT aflibercept is the first listed.
NCT02980874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02980874 about?
NCT02980874 is a clinical study titled "Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO". This is a Phase 3, multicenter, randomized, masked, controlled, parallel group study of 12 months duration in treatment naïve subjects with RVO.
What is the current status of trial NCT02980874?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 460 participants. The study started on 2017-01-31. Estimated completion is 2018-12-10.
What interventions are being tested in trial NCT02980874?
The interventions under investigation include: IVT aflibercept (DRUG), suprachoroidal CLS-TA (DRUG), suprachoroidal sham (DRUG).
Who is sponsoring clinical trial NCT02980874?
This trial is sponsored by Clearside Biomedical, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.